Anti-SSA antibodies, which are the primary serological marker of SS, were detected in 20% of IBM patients, while anti-cN1A antibodies, a valuable biomarker for IBM, were also found in 12% of SS patients (2, 18, 19). This evidence concerns the gene NT5C1A and synovial sarcoma.